Drugmaker executives have projected confidence they can mitigate the impact of any levies Trump imposes on the industry. Yet ...

The Zensights Federated Healthcare Advisory Panel explores how shifting global dynamics are reshaping access and strategic ...

Pfizer CEO Albert Bourla said Tuesday that uncertainty surrounding President Donald Trump’s proposed pharmaceutical tariffs is discouraging the company from making additional investments in U.S.

Research teams across the country are now building on this homegrown innovation to expand the potential of RNA vaccines ...

The government is putting money into a new kind of vaccine that could work against different types of viruses with just one ...

The company removed experimental drugs for Alzheimer’s, migraine and pain from its pipeline to focus more resources on “core ...

With attention focused on their recently approved drugs for transthyretin amyloid cardiomyopathy (ATTR-CM), there was a ...

Pfizer and Arvinas have axed two phase 3 trials from their estrogen receptor (ER) degrader R&D plan in the wake of mixed data ...

Neoadjuvant immunotherapy alone resulted in significant treatment response among most patients with mismatch-repair-deficient ...

The project, more than a decade in the making, replaces a business campus that was once home to Johnson & Johnson, Pfizer and ...

There's no need to track down complicated and obscure businesses. Some of the market's best income-producing stocks are ...

When it comes to vaccination, the COVID-19 pandemic divided American society. President Donald Trump and his new Health and ...